Oncopeptides Ab Stock Net Income
| ONPPFDelisted Stock | USD 0.27 0.00 0.00% |
Fundamental analysis of Oncopeptides allows traders to better anticipate movements in Oncopeptides' stock price by examining its financial health and performance throughout various phases of its business cycle.
Oncopeptides |
Oncopeptides AB Company Net Income Analysis
Oncopeptides' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Oncopeptides Net Income | (1.43 B) |
Most of Oncopeptides' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncopeptides AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Oncopeptides AB reported net income of (1.43 Billion). This is 519.1% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Oncopeptides Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncopeptides' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oncopeptides could also be used in its relative valuation, which is a method of valuing Oncopeptides by comparing valuation metrics of similar companies.Oncopeptides is currently under evaluation in net income category among its peers.
Oncopeptides Fundamentals
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 75.14 M | |||
| Shares Outstanding | 90.37 M | |||
| Shares Owned By Insiders | 10.76 % | |||
| Shares Owned By Institutions | 47.54 % | |||
| Price To Book | 14.19 X | |||
| Price To Sales | 17.15 X | |||
| Revenue | 118.3 M | |||
| Gross Profit | 74.16 M | |||
| EBITDA | (1.41 B) | |||
| Net Income | (1.43 B) | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 1.71 X | |||
| Cash Flow From Operations | (1.52 B) | |||
| Number Of Employees | 40 | |||
| Beta | -0.67 | |||
| Market Capitalization | 245.84 M | |||
| Total Asset | 439.38 M | |||
| Z Score | -9.9 | |||
| Net Asset | 439.38 M |
About Oncopeptides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncopeptides AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncopeptides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncopeptides AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Oncopeptides Pink Sheet
If you are still planning to invest in Oncopeptides AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncopeptides' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |